NO315903B1 - Immunokonjugater, fremgangsmåte for fremstilling derav, farmasöytiske preparater, samt anvendelse av immunokonjugatene for fremstilling avlegemidler mot tumorer - Google Patents
Immunokonjugater, fremgangsmåte for fremstilling derav, farmasöytiske preparater, samt anvendelse av immunokonjugatene for fremstilling avlegemidler mot tumorer Download PDFInfo
- Publication number
- NO315903B1 NO315903B1 NO19944980A NO944980A NO315903B1 NO 315903 B1 NO315903 B1 NO 315903B1 NO 19944980 A NO19944980 A NO 19944980A NO 944980 A NO944980 A NO 944980A NO 315903 B1 NO315903 B1 NO 315903B1
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- mab
- cells
- immunoconjugates
- tumor
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title claims description 55
- 206010028980 Neoplasm Diseases 0.000 title claims description 36
- 238000000034 method Methods 0.000 title claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
- 229940079593 drug Drugs 0.000 title claims description 4
- 239000003814 drug Substances 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims description 65
- 108010002350 Interleukin-2 Proteins 0.000 claims description 28
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 24
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 24
- 102000037865 fusion proteins Human genes 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 15
- 230000004927 fusion Effects 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 241001529936 Murinae Species 0.000 claims description 6
- 102000053602 DNA Human genes 0.000 claims description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 description 44
- 102000004127 Cytokines Human genes 0.000 description 43
- 102000000588 Interleukin-2 Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 24
- 239000013598 vector Substances 0.000 description 22
- 239000006228 supernatant Substances 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 17
- 102000001301 EGF receptor Human genes 0.000 description 13
- 108060006698 EGF receptor Proteins 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 108010002586 Interleukin-7 Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 101150050446 pelB gene Proteins 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 241000588701 Pectobacterium carotovorum Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000050 cytotoxic potential Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- -1 olive oils Chemical compound 0.000 description 2
- 101150040383 pel2 gene Proteins 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93120865 | 1993-12-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO944980D0 NO944980D0 (no) | 1994-12-22 |
NO944980L NO944980L (no) | 1995-06-26 |
NO315903B1 true NO315903B1 (no) | 2003-11-10 |
Family
ID=8213530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19944980A NO315903B1 (no) | 1993-12-24 | 1994-12-22 | Immunokonjugater, fremgangsmåte for fremstilling derav, farmasöytiske preparater, samt anvendelse av immunokonjugatene for fremstilling avlegemidler mot tumorer |
Country Status (19)
Country | Link |
---|---|
US (1) | US6979726B1 (xx) |
EP (1) | EP0659439B1 (xx) |
JP (2) | JPH07223968A (xx) |
KR (1) | KR950016781A (xx) |
AT (1) | ATE207366T1 (xx) |
AU (1) | AU688817B2 (xx) |
CA (1) | CA2138928C (xx) |
CZ (1) | CZ289099B6 (xx) |
DE (1) | DE69428764T2 (xx) |
DK (1) | DK0659439T3 (xx) |
ES (1) | ES2166368T3 (xx) |
HU (1) | HU219680B (xx) |
NO (1) | NO315903B1 (xx) |
PL (1) | PL178793B1 (xx) |
PT (1) | PT659439E (xx) |
RU (1) | RU2129018C1 (xx) |
SK (1) | SK283494B6 (xx) |
UA (1) | UA41888C2 (xx) |
ZA (1) | ZA9410282B (xx) |
Families Citing this family (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
WO1998011241A1 (en) * | 1996-09-16 | 1998-03-19 | Merck Patent Gmbh | Oligocistronic expression system for the production of heteromeric proteins |
PT1189641E (pt) | 1999-06-25 | 2009-11-04 | Genentech Inc | Anticorpos anti-erbb2 humanizados e tratamento com anticorpos anti-erbb2 |
CN101711866A (zh) | 2002-07-15 | 2010-05-26 | 健泰科生物技术公司 | 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法 |
US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
AU2004309050B2 (en) | 2003-12-30 | 2010-10-14 | Merck Patent Gmbh | IL-7 fusion proteins |
US8017321B2 (en) | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
ATE540696T1 (de) | 2004-04-08 | 2012-01-15 | David B Agus | Erbb2-antagonisten für die tumorschmerztherapie |
ES2537631T3 (es) | 2004-05-27 | 2015-06-10 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
CA2567520A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Maytansinoid-antibody conjugates |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
ES2710439T3 (es) | 2005-01-21 | 2019-04-25 | Genentech Inc | Dosificación fija de anticuerpos HER |
AU2006216732C1 (en) | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
AR053272A1 (es) | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
AU2006332138B2 (en) | 2005-12-30 | 2012-03-22 | Merck Patent Gmbh | Interleukin-12p40 variants with improved stability |
KR101397290B1 (ko) | 2005-12-30 | 2014-05-21 | 메르크 파텐트 게엠베하 | 감소한 면역원성을 가지는 항-cd19 항체 |
ATE509096T1 (de) * | 2006-06-16 | 2011-05-15 | Onco Therapy Science Inc | Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält |
CA2662236A1 (en) | 2006-09-12 | 2008-03-20 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2592156B1 (en) | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
WO2011020783A2 (en) * | 2009-08-17 | 2011-02-24 | Roche Glycart Ag | Targeted immunoconjugates |
WO2011069104A2 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
EP2523957A1 (en) | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
PL2536748T3 (pl) | 2010-02-18 | 2015-01-30 | Genentech Inc | Antagoniści neureguliny i ich zastosowanie w leczeniu nowotworu |
WO2011112935A2 (en) * | 2010-03-12 | 2011-09-15 | The Regents Of The University Of California | Antibody fusion proteins with disrupted heparin-binding activity |
CN102869359A (zh) | 2010-03-17 | 2013-01-09 | 弗·哈夫曼-拉罗切有限公司 | 咪唑并吡啶和嘌呤化合物、组合物和使用方法 |
WO2011130654A1 (en) | 2010-04-16 | 2011-10-20 | Genentech, Inc. | Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
MX2013002084A (es) | 2010-08-31 | 2013-05-09 | Genentech Inc | Biomarcadores y metodos de tratamiento. |
CN103209695A (zh) | 2010-09-15 | 2013-07-17 | 弗·哈夫曼-拉罗切有限公司 | 氮杂苯并噻唑化合物、组合物及应用方法 |
UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
SG189929A1 (en) | 2010-10-29 | 2013-06-28 | Immunogen Inc | Novel egfr-binding molecules and immunoconjugates thereof |
WO2012058592A2 (en) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Non-antagonistic egfr-binding molecules and immunoconjugates thereof |
WO2012065161A2 (en) | 2010-11-12 | 2012-05-18 | Scott & White Healthcare | Antibodies to tumor endothelial marker 8 |
WO2012066061A1 (en) | 2010-11-19 | 2012-05-24 | F. Hoffmann-La Roche Ag | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
MX2014001595A (es) | 2011-08-12 | 2014-04-14 | Hoffmann La Roche | Compuestos de imidazol, composiciones y metodos de uso. |
WO2013025853A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
KR20140082710A (ko) | 2011-09-20 | 2014-07-02 | 에프. 호프만-라 로슈 아게 | 이미다조피리딘 화합물, 조성물 및 사용 방법 |
KR20140105765A (ko) | 2011-11-21 | 2014-09-02 | 이뮤노젠 아이엔씨 | EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법 |
JP2015500638A (ja) | 2011-11-30 | 2015-01-08 | ジェネンテック, インコーポレイテッド | 癌におけるerbb3変異 |
JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Her3阻害剤に関する診断及び治療 |
EP2958592A1 (en) | 2013-02-22 | 2015-12-30 | F. Hoffmann-La Roche AG | Methods of treating cancer and preventing drug resistance |
US9925240B2 (en) | 2013-03-06 | 2018-03-27 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
KR20150130491A (ko) | 2013-03-13 | 2015-11-23 | 제넨테크, 인크. | 피라졸로 화합물 및 그것의 용도 |
US20140271634A1 (en) | 2013-03-14 | 2014-09-18 | The Regents Of The University Of California | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
BR112015022604A2 (pt) | 2013-03-14 | 2017-10-24 | Genentech Inc | usos de um modulador de modificador de cromatina e um antagonista de egfr |
KR102305226B1 (ko) * | 2013-03-15 | 2021-09-29 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 항-egfr 항체 약물 접합체 제형 |
KR20150130451A (ko) | 2013-03-15 | 2015-11-23 | 제넨테크, 인크. | 암 치료 방법 및 항암제 내성 예방을 위한 방법 |
CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
RU2016112568A (ru) | 2013-09-05 | 2017-10-06 | Дженентек, Инк. | Антипролиферативные соединения |
WO2015049325A1 (en) | 2013-10-03 | 2015-04-09 | F. Hoffmann-La Roche Ag | Therapeutic inhibitors of cdk8 and uses thereof |
TWI658052B (zh) | 2013-10-18 | 2019-05-01 | 美商建南德克公司 | 抗-rspo抗體及使用方法 |
MX2016007965A (es) | 2013-12-17 | 2016-10-28 | Genentech Inc | Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1. |
NZ720515A (en) | 2013-12-17 | 2022-12-23 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
JP2017516458A (ja) | 2014-03-24 | 2017-06-22 | ジェネンテック, インコーポレイテッド | c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関 |
JP6588461B2 (ja) | 2014-03-31 | 2019-10-09 | ジェネンテック, インコーポレイテッド | 抗血管新生剤及びox40結合アゴニストを含む併用療法 |
CR20160500A (es) | 2014-03-31 | 2016-12-14 | Genentech Inc | Anticuerpos anti-ox40 y métodos de uso |
RU2701341C2 (ru) * | 2014-04-03 | 2019-09-25 | Селлектис | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака |
EP3189046B1 (en) | 2014-09-05 | 2020-08-26 | Genentech, Inc. | Therapeutic compounds and uses thereof |
JP2017529358A (ja) | 2014-09-19 | 2017-10-05 | ジェネンテック, インコーポレイテッド | がんの処置のためのcbp/ep300阻害剤およびbet阻害剤の使用 |
EP3204379B1 (en) | 2014-10-10 | 2019-03-06 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
JP2017536842A (ja) | 2014-11-03 | 2017-12-14 | ジェネンテック, インコーポレイテッド | Ox40アゴニスト治療薬の有効性及び評価を予測するための方法及びバイオマーカー |
US20160161485A1 (en) | 2014-11-03 | 2016-06-09 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
CN107073126A (zh) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和tigit抑制剂的组合疗法 |
MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
CN107108613B (zh) | 2014-11-10 | 2020-02-25 | 基因泰克公司 | 布罗莫结构域抑制剂及其用途 |
MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
BR112017010198A2 (pt) | 2014-11-17 | 2017-12-26 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1 |
CN107531690B (zh) | 2014-11-27 | 2020-11-06 | 基因泰克公司 | 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物 |
WO2016091891A1 (en) | 2014-12-09 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against axl |
KR20170094165A (ko) | 2014-12-23 | 2017-08-17 | 제넨테크, 인크. | 화학요법-내성 암을 치료 및 진단하는 조성물 및 방법 |
EP3240908A2 (en) | 2014-12-30 | 2017-11-08 | F. Hoffmann-La Roche AG | Methods and compositions for prognosis and treatment of cancers |
CN107406429B (zh) | 2015-01-09 | 2021-07-06 | 基因泰克公司 | 哒嗪酮衍生物及其在治疗癌症中的用途 |
JP6889661B2 (ja) | 2015-01-09 | 2021-06-18 | ジェネンテック, インコーポレイテッド | 4,5−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ(kdm2b)インヒビターとしてのその使用 |
CN107406414B (zh) | 2015-01-09 | 2022-04-19 | 基因泰克公司 | 作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物 |
EP3244923A4 (en) | 2015-01-12 | 2018-09-05 | Children's Medical Center Corporation | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
WO2016123391A1 (en) | 2015-01-29 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
CN107438593B (zh) | 2015-01-30 | 2020-10-30 | 基因泰克公司 | 治疗化合物及其用途 |
WO2016131856A1 (en) * | 2015-02-18 | 2016-08-25 | F. Hoffmann-La Roche Ag | Immunoconjugates for specific induction of t cell cytotoxicity against a target cell |
MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
JP6955445B2 (ja) | 2015-04-07 | 2021-10-27 | ジェネンテック, インコーポレイテッド | アゴニスト性の活性を有する抗原結合複合体及びその使用方法 |
EP3294770B2 (en) | 2015-05-12 | 2024-03-20 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
IL255372B (en) | 2015-05-29 | 2022-07-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer |
JP2018521019A (ja) | 2015-06-08 | 2018-08-02 | ジェネンテック, インコーポレイテッド | 抗ox40抗体を使用して癌を治療する方法 |
CA2988420A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
AU2016280070B2 (en) | 2015-06-17 | 2022-09-15 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes |
ES2862727T3 (es) | 2015-08-26 | 2021-10-07 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | Compuestos tricíclicos condensados como inhibidores de proteínas quinasas |
WO2017053748A2 (en) | 2015-09-25 | 2017-03-30 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
PL3978500T3 (pl) | 2015-12-16 | 2024-03-11 | Genentech, Inc. | Sposób wytwarzania tricyklicznych związków inhibitorów pi3k |
AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
JP6821693B2 (ja) | 2016-02-29 | 2021-01-27 | ジェネンテック, インコーポレイテッド | がんのための治療方法及び診断方法 |
EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
KR20190003957A (ko) | 2016-04-15 | 2019-01-10 | 제넨테크, 인크. | 암 모니터링 및 치료 방법 |
MX2018012492A (es) | 2016-04-15 | 2019-06-06 | Genentech Inc | Métodos para monitorear y tratar el cáncer. |
EP3443114A1 (en) | 2016-04-15 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
CN109476663B (zh) | 2016-05-24 | 2021-11-09 | 基因泰克公司 | 用于治疗癌症的吡唑并吡啶衍生物 |
CN109476641B (zh) | 2016-05-24 | 2022-07-05 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
WO2017214373A1 (en) | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
AU2017339517B2 (en) | 2016-10-06 | 2024-03-14 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
CN110267678A (zh) | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
AU2018228873A1 (en) | 2017-03-01 | 2019-08-29 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
SG11201908929VA (en) * | 2017-03-31 | 2019-10-30 | Univ Leland Stanford Junior | Synthekine compositions and methods of use |
CN110505883A (zh) | 2017-04-13 | 2019-11-26 | 豪夫迈·罗氏有限公司 | 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂 |
AU2018316343A1 (en) | 2017-08-11 | 2020-02-13 | Genentech, Inc. | Anti-CD8 antibodies and uses thereof |
EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
US11369608B2 (en) | 2017-10-27 | 2022-06-28 | University Of Virginia Patent Foundation | Compounds and methods for regulating, limiting, or inhibiting AVIL expression |
KR20200075860A (ko) | 2017-11-06 | 2020-06-26 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
MX2020008882A (es) | 2018-02-26 | 2021-01-08 | Genentech Inc | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. |
CA3100200A1 (en) | 2018-05-21 | 2019-11-28 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
CA3103017A1 (en) | 2018-06-23 | 2019-12-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
WO2020018789A1 (en) | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
EP3847154A1 (en) | 2018-09-03 | 2021-07-14 | F. Hoffmann-La Roche AG | Carboxamide and sulfonamide derivatives useful as tead modulators |
WO2020061060A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
EP3857230B1 (en) | 2018-09-21 | 2023-06-07 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
CA3116324A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
US20220098262A1 (en) * | 2018-12-13 | 2022-03-31 | Bang DING | ANTIBODY-TUMOR NECROSIS FACTOR alpha FUSION PROTEIN AND ITS PREPARATION AND APPLICATIONS |
EP3921443A1 (en) | 2019-02-08 | 2021-12-15 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
EP3931220A1 (en) | 2019-02-27 | 2022-01-05 | F. Hoffmann-La Roche AG | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
AU2020227319A1 (en) | 2019-02-27 | 2021-09-09 | Epiaxis Therapeutics Pty Ltd | Methods and agents for assessing T-cell function and predicting response to therapy |
WO2020223233A1 (en) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Prognostic and therapeutic methods for colorectal cancer |
AU2020270376A1 (en) | 2019-05-03 | 2021-10-07 | Genentech, Inc. | Methods of treating cancer with an anti-PD-L1 antibody |
CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
US20230192853A1 (en) | 2019-09-04 | 2023-06-22 | Genentech, Inc. | Cd8 binding agents and uses thereof |
PE20221110A1 (es) | 2019-09-27 | 2022-07-11 | Genentech Inc | Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 |
EP4051674A1 (en) | 2019-10-29 | 2022-09-07 | F. Hoffmann-La Roche AG | Bifunctional compounds for the treatment of cancer |
CA3155922A1 (en) | 2019-11-06 | 2021-05-14 | Huang Huang | Diagnostic and therapeutic methods for treatment of hematologic cancers |
EP4058435A1 (en) | 2019-11-13 | 2022-09-21 | Genentech, Inc. | Therapeutic compounds and methods of use |
IL293423A (en) | 2019-12-13 | 2022-07-01 | Genentech Inc | Anti-ly6g6d antibodies and methods of use |
AU2020408562A1 (en) | 2019-12-20 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
CN115698717A (zh) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
EP4143345A1 (en) | 2020-04-28 | 2023-03-08 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
EP3915576A1 (en) | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
AU2021293038A1 (en) | 2020-06-16 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating triple-negative breast cancer |
WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
US20230266322A1 (en) | 2020-06-30 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
WO2022002873A1 (en) | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
EP3939999A1 (en) | 2020-07-14 | 2022-01-19 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof |
US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
JP2023536602A (ja) | 2020-08-03 | 2023-08-28 | ジェネンテック, インコーポレイテッド | リンパ腫のための診断及び治療方法 |
EP4196612A1 (en) | 2020-08-12 | 2023-06-21 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
JP2023544407A (ja) | 2020-10-05 | 2023-10-23 | ジェネンテック, インコーポレイテッド | 抗FcRH5/抗CD3二重特異性抗体による処置のための投与 |
US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
JP2024506339A (ja) | 2021-02-12 | 2024-02-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための二環式テトラヒドロアゼピン誘導体 |
JP2024520457A (ja) | 2021-05-25 | 2024-05-24 | エラスカ・インコーポレイテッド | 硫黄含有ヘテロ芳香族三環式kras阻害剤 |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
EP4384522A1 (en) | 2021-08-10 | 2024-06-19 | Erasca, Inc. | Selective kras inhibitors |
TW202340212A (zh) | 2021-11-24 | 2023-10-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
EP4253418A1 (en) | 2022-03-29 | 2023-10-04 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
TW202417001A (zh) | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫吖呯衍生物 |
TW202417439A (zh) | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫噻吖呯衍生物 |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024085242A2 (en) | 2022-10-21 | 2024-04-25 | Kawasaki Institute Of Industrial Promotion | Non-fouling or super stealth vesicle |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
EP4406973A1 (en) | 2023-01-27 | 2024-07-31 | Fundació Privada Institut de Recerca de la SIDA-Caixa | Antibodies and uses thereof for the treatment of infections caused by enveloped viruses |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
ZA902949B (en) * | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
EP0491007B1 (en) * | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
JPH09506761A (ja) * | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
DK0531472T3 (da) * | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
WO1993000917A1 (en) * | 1991-07-05 | 1993-01-21 | Seragen, Inc. | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis |
PT586002E (pt) * | 1992-08-18 | 2000-07-31 | Centro Inmunologia Molecular | Anticorpos monoclonais que reconhecem o receptor do factor de crescimento epidermico, celulas e metodos para a sua producao e composicoes que os incluem |
DK139193D0 (da) | 1993-09-24 | 1993-12-13 | Hartmann As Brdr | Rektangulaer aegbakke |
DE69529649T2 (de) * | 1994-03-17 | 2003-12-18 | Merck Patent Gmbh | Anti-egfr einkettige fvs und anti-egfr antikoerper |
-
1994
- 1994-12-14 DK DK94119712T patent/DK0659439T3/da active
- 1994-12-14 PT PT94119712T patent/PT659439E/pt unknown
- 1994-12-14 EP EP94119712A patent/EP0659439B1/en not_active Expired - Lifetime
- 1994-12-14 ES ES94119712T patent/ES2166368T3/es not_active Expired - Lifetime
- 1994-12-14 AT AT94119712T patent/ATE207366T1/de not_active IP Right Cessation
- 1994-12-14 DE DE69428764T patent/DE69428764T2/de not_active Expired - Lifetime
- 1994-12-19 SK SK1562-94A patent/SK283494B6/sk not_active IP Right Cessation
- 1994-12-20 AU AU81593/94A patent/AU688817B2/en not_active Ceased
- 1994-12-21 UA UA94129229A patent/UA41888C2/uk unknown
- 1994-12-22 CA CA002138928A patent/CA2138928C/en not_active Expired - Fee Related
- 1994-12-22 JP JP6320978A patent/JPH07223968A/ja active Pending
- 1994-12-22 NO NO19944980A patent/NO315903B1/no not_active IP Right Cessation
- 1994-12-22 PL PL94306474A patent/PL178793B1/pl not_active IP Right Cessation
- 1994-12-22 ZA ZA9410282A patent/ZA9410282B/xx unknown
- 1994-12-23 KR KR1019940036168A patent/KR950016781A/ko not_active Application Discontinuation
- 1994-12-23 HU HU9403784A patent/HU219680B/hu not_active IP Right Cessation
- 1994-12-23 RU RU94045281A patent/RU2129018C1/ru not_active IP Right Cessation
- 1994-12-23 US US08/362,951 patent/US6979726B1/en not_active Expired - Fee Related
- 1994-12-27 CZ CZ19943306A patent/CZ289099B6/cs not_active IP Right Cessation
-
2006
- 2006-06-28 JP JP2006178409A patent/JP2006298936A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PT659439E (pt) | 2002-04-29 |
SK156294A3 (en) | 1995-07-11 |
AU688817B2 (en) | 1998-03-19 |
EP0659439B1 (en) | 2001-10-24 |
NO944980L (no) | 1995-06-26 |
DE69428764D1 (de) | 2001-11-29 |
CZ330694A3 (en) | 1995-10-18 |
ZA9410282B (en) | 1995-08-29 |
RU94045281A (ru) | 1996-11-10 |
NO944980D0 (no) | 1994-12-22 |
AU8159394A (en) | 1995-06-29 |
EP0659439A3 (en) | 1996-12-04 |
EP0659439A2 (en) | 1995-06-28 |
CA2138928A1 (en) | 1995-06-25 |
ATE207366T1 (de) | 2001-11-15 |
PL306474A1 (en) | 1995-06-26 |
HU9403784D0 (en) | 1995-02-28 |
US6979726B1 (en) | 2005-12-27 |
HU219680B (hu) | 2001-06-28 |
JP2006298936A (ja) | 2006-11-02 |
KR950016781A (ko) | 1995-07-20 |
DE69428764T2 (de) | 2002-06-20 |
CA2138928C (en) | 2009-02-17 |
PL178793B1 (pl) | 2000-06-30 |
JPH07223968A (ja) | 1995-08-22 |
DK0659439T3 (da) | 2002-01-14 |
SK283494B6 (sk) | 2003-08-05 |
RU2129018C1 (ru) | 1999-04-20 |
UA41888C2 (uk) | 2001-10-15 |
CZ289099B6 (cs) | 2001-11-14 |
HUT70471A (en) | 1995-10-30 |
ES2166368T3 (es) | 2002-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO315903B1 (no) | Immunokonjugater, fremgangsmåte for fremstilling derav, farmasöytiske preparater, samt anvendelse av immunokonjugatene for fremstilling avlegemidler mot tumorer | |
EP0706799B1 (en) | Immunoconjugates II | |
Gillies et al. | Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases | |
ES2534085T3 (es) | Inmunoconjugados dirigidos | |
EP0574395B1 (en) | Cytokine immunoconjugates | |
JP3553933B2 (ja) | 高められた活性を有する組換シュードモナス外毒素 | |
CN1318450C (zh) | 修饰和嵌合的超抗原及其用途 | |
CA3043146C (en) | Il2 and tnf mutant immunoconjugates | |
CA2097416A1 (en) | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diphtheria toxin | |
WO2020070150A1 (en) | Il2 immunoconjugates | |
Reisfeld et al. | Recombinant antibody fusion proteins for cancer immunotherapy | |
CN117042809A (zh) | 抗her2抗体-免疫激动剂缀合物及其应用 | |
Hess | Targeted delivery of immunomodulatory proteins: evaluation of novel antibody-chemokine and antibody-cytokine fusion proteins for cancer therapy | |
Gupta et al. | Immunomodulation by interleukin-2 receptor targeted therapy | |
Gillies | Designing immunocytokines: genetically engineered fusion proteins for targeted immune therapy | |
Gillies | Recombinant Protein Drugs 129 ed. by P. Buckel© 2001 Birkhäuser Verlag/Switzerland |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |